Rocket Pharmaceu Stock Price, News & Analysis

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) reported strong progress in Q3 2022, particularly in its Phase 1 trial for Danon Disease, where RP-A501 showed durable therapeutic effects. The company anticipates FDA feedback for its Phase 2 pivotal study design by Q4 2022. Additionally, Rocket plans to acquire Renovacor to enhance its AAV-based cardiac gene therapy capabilities. With $306.5M in cash and recent equity financing boosting its runway into H2 2024, the company is well-positioned for ongoing clinical trials and regulatory filings in 2023.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) announced data presentations at the upcoming 75th American Heart Association Annual Meeting (Nov 5-7, 2022) and the 64th American Society of Hematology Annual Meeting (Dec 10-13, 2022). Data will focus on its gene therapies for rare diseases, including RP-A501 for Danon Disease and RP-L102 for Fanconi Anemia. Presenters include experts from renowned institutions. The company aims to address high unmet medical needs in pediatric populations with genetic disorders.

Rocket Pharmaceuticals (NASDAQ: RCKT) announced that Chief Business Officer Raj Prabhakar will present at the 2022 Cell & Gene Meeting on October 11 at 2:30 p.m. PT in Carlsbad, CA. The presentation aims to highlight the company's pipeline of genetic therapies targeting rare childhood disorders. A live audio webcast will be available for registered attendees, with on-demand viewing post-event. Rocket focuses on innovative treatments for conditions like Fanconi Anemia and Danon Disease, showcasing its commitment to addressing unmet medical needs.

Rocket Pharmaceuticals (NASDAQ: RCKT) has announced the pricing of a public offering of 6,800,000 shares at $14.75 each, aiming to raise approximately $100.3 million before expenses. The offering is set to close around October 6, 2022. Additionally, underwriters may purchase up to 1,020,000 additional shares within 30 days. This move is intended to bolster Rocket’s pipeline of genetic therapies targeting rare childhood disorders.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has initiated an underwritten public offering of $100 million in common stock, with a potential additional $15 million option for underwriters. The offering will be managed by Morgan Stanley, J.P. Morgan, and SVB Securities. This offering is subject to market conditions, and all shares will be sold by Rocket. The process follows a shelf registration statement previously filed with the SEC. The final terms will be disclosed in a subsequent prospectus supplement.

Rocket Pharmaceuticals (RCKT) announced positive updates from its Phase 1 Danon Disease Trial for RP-A501, showing initial improvements in pediatric patients and sustained clinical benefits in adults. The trial includes both safety and efficacy data, indicating that RP-A501 is generally well tolerated across cohorts. Notably, patients exhibited significant reductions in heart failure markers like BNP and improvements in NYHA class. The company anticipates support for advancing to a Phase 2 pivotal study with FDA feedback expected later this year.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical biotech firm focused on genetic therapies for rare childhood disorders, will have CEO Gaurav Shah participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on October 4 at 2:00 p.m. ET, in New York City. The event will be accessible via a live audio webcast on the company's website, with a replay available later. Rocket is advancing therapies for conditions like Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and Danon Disease.

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) has announced the acquisition of Renovacor, Inc. (NYSE: RCOR) in an all-stock transaction valued at approximately $2.60 per share. This acquisition aims to enhance Rocket's leadership in AAV-based cardiac gene therapy, targeting BAG3-associated dilated cardiomyopathy, which presents a significant unmet medical need. The deal is expected to close by Q1 2023, pending shareholder and regulatory approvals. Rocket anticipates the acquisition will create strong synergies, adding approximately $38M in projected cash at closing and extending its cash runway into Q2 2024.